Desai Aakash, Khataniar Himsikhar, Tabaku Fjona, Hashash Jana G, Farraye Francis A, Kochhar Gursimran S
Division of Gastroenterology, Hepatology and Nutrition, Allegheny Health Network, 1307 Federal St., Suite 305, Pittsburgh, PA, 15212, USA.
Drexel University College of Medicine, Philadelphia, PA, USA.
Indian J Gastroenterol. 2025 Jul 19. doi: 10.1007/s12664-025-01835-y.
There is limited data about tirzepatide's (TZP) efficacy for weight loss in patients with inflammatory bowel disease (IBD).
A retrospective cohort study was conducted using the US Collaborative Network in patients with IBD on TZP between January 5, 2022 and December 31, 2023. The objective was to assess mean total body weight (TBW) change in pounds (lbs) in the IBD TZP cohort compared to the non-IBD TZP cohort and IBD cohort with weight loss surgery (WLS) from baseline to between six and 15 months. 1:1 propensity score matching was performed for demographics, comorbid conditions, body mass index (BMI) and body weight.
There were 274 patients in the IBD TZP cohort (mean age 53.6 ± 11.9, 66.4% diabetes mellitus, BMI 38.3 ± 7.7 kg/m). There was no difference in the TBW change between the IBD and non-IBD cohort on TZP (-21 lbs [ 95% CI -30 to -12] vs. -21 lbs [-30 to -11], p = 1.0). There was no difference in the TBW based on time interval, IBD type, IBD medications, surgery and TZP dose. There was a lower TBW change compared to the IBD WLS cohort (-21 lbs [-36 to -5] vs. -55 lbs [-68 to -41], p < 0.0001). There was higher TBW change with 15 mg TZP (-29 lbs [-45 to -12]) compared to 5-10 mg TZP (-15 lbs [-36 to 6]), however, lower compared to the IBD WLS cohort.
TZP use was associated with a similar mean weight loss of > 10% in patients with IBD compared to patients without IBD, however lower compared to WLS.
关于替尔泊肽（TZP）对炎症性肠病（IBD）患者体重减轻疗效的数据有限。
采用美国协作网络进行一项回顾性队列研究，研究对象为2022年1月5日至2023年12月31日期间接受TZP治疗的IBD患者。目的是评估IBD TZP队列与非IBD TZP队列以及接受减肥手术（WLS）的IBD队列从基线到6至15个月期间以磅（lbs）为单位的平均总体重（TBW）变化。对人口统计学、合并症、体重指数（BMI）和体重进行1:1倾向评分匹配。
IBD TZP队列中有274例患者（平均年龄53.6±11.9岁，66.4%患有糖尿病，BMI为38.3±7.7kg/m）。接受TZP治疗的IBD队列和非IBD队列之间的TBW变化无差异（-21磅[95%CI -30至-12]对-21磅[-30至-11]，p = 1.0）。基于时间间隔、IBD类型、IBD药物、手术和TZP剂量的TBW无差异。与IBD WLS队列相比，TBW变化较低（-21磅[-36至-5]对-55磅[-68至-41]，p < 0.0001）。与5-10mg TZP（-15磅[-36至6]）相比，15mg TZP的TBW变化更高（-29磅[-45至-12]），但与IBD WLS队列相比更低。
与非IBD患者相比，IBD患者使用TZP的平均体重减轻相似，均>10%，但与WLS相比更低。
